BARD1 Life Sciences Competitors

(BUX) (CNSX:BUX) and BARD1 Life Sciences (ASX:BD1) are both medical companies, but which is the superior business? We will compare the two businesses based on the strength of their profitability, analyst recommendations, dividends, risk, earnings, valuation and institutional ownership.

Earnings & Valuation

This table compares (BUX) and BARD1 Life Sciences' gross revenue, earnings per share (EPS) and valuation.

(BUX) has higher earnings, but lower revenue than BARD1 Life Sciences.

Profitability

This table compares (BUX) and BARD1 Life Sciences' net margins, return on equity and return on assets.

Analyst Ratings

This is a breakdown of recent ratings and target prices for (BUX) and BARD1 Life Sciences, as provided by MarketBeat.com.

Summary

BARD1 Life Sciences beats (BUX) on 1 of the 1 factors compared between the two stocks.

BARD1 Life Sciences (ASX:BD1) and 12144 (CNSX:IME) are both medical companies, but which is the superior stock? We will contrast the two companies based on the strength of their risk, analyst recommendations, dividends, institutional ownership, valuation, earnings and profitability.

Analyst Ratings

This is a summary of current ratings and price targets for BARD1 Life Sciences and 12144, as reported by MarketBeat.

Earnings and Valuation

This table compares BARD1 Life Sciences and 12144's top-line revenue, earnings per share and valuation.

12144 has lower revenue, but higher earnings than BARD1 Life Sciences.

Profitability

This table compares BARD1 Life Sciences and 12144's net margins, return on equity and return on assets.

Summary

BARD1 Life Sciences beats 12144 on 1 of the 1 factors compared between the two stocks.

Charles River Laboratories International (CNSX:CRL) and BARD1 Life Sciences (ASX:BD1) are both medical companies, but which is the better business? We will compare the two businesses based on the strength of their risk, profitability, earnings, dividends, institutional ownership, analyst recommendations and valuation.

Earnings and Valuation

This table compares Charles River Laboratories International and BARD1 Life Sciences' gross revenue, earnings per share and valuation.

Charles River Laboratories International has higher earnings, but lower revenue than BARD1 Life Sciences.

Profitability

This table compares Charles River Laboratories International and BARD1 Life Sciences' net margins, return on equity and return on assets.

Analyst Ratings

This is a breakdown of recent ratings for Charles River Laboratories International and BARD1 Life Sciences, as provided by MarketBeat.

Summary

BARD1 Life Sciences beats Charles River Laboratories International on 1 of the 1 factors compared between the two stocks.

BARD1 Life Sciences (ASX:BD1) and Cryosite (ASX:CTE) are both medical companies, but which is the superior business? We will compare the two businesses based on the strength of their profitability, institutional ownership, earnings, valuation, dividends, analyst recommendations and risk.

Profitability

This table compares BARD1 Life Sciences and Cryosite's net margins, return on equity and return on assets.

Analyst Recommendations

This is a breakdown of recent recommendations and price targets for BARD1 Life Sciences and Cryosite, as provided by MarketBeat.

Valuation and Earnings

This table compares BARD1 Life Sciences and Cryosite's gross revenue, earnings per share and valuation.

Cryosite has higher revenue and earnings than BARD1 Life Sciences.

Summary

Cryosite beats BARD1 Life Sciences on 3 of the 3 factors compared between the two stocks.

dorsaVi (ASX:DVL) and BARD1 Life Sciences (ASX:BD1) are both medical companies, but which is the better investment? We will contrast the two businesses based on the strength of their earnings, institutional ownership, dividends, risk, valuation, profitability and analyst recommendations.

Valuation and Earnings

This table compares dorsaVi and BARD1 Life Sciences' revenue, earnings per share (EPS) and valuation.

dorsaVi has higher revenue and earnings than BARD1 Life Sciences.

Analyst Recommendations

This is a summary of recent ratings and recommmendations for dorsaVi and BARD1 Life Sciences, as reported by MarketBeat.

Profitability

This table compares dorsaVi and BARD1 Life Sciences' net margins, return on equity and return on assets.

Summary

dorsaVi beats BARD1 Life Sciences on 3 of the 3 factors compared between the two stocks.

BARD1 Life Sciences (ASX:BD1) and Epigenomics (OTCMKTS:EPGNY) are both medical companies, but which is the better business? We will compare the two companies based on the strength of their earnings, risk, institutional ownership, profitability, valuation, analyst recommendations and dividends.

Analyst Recommendations

This is a breakdown of recent ratings for BARD1 Life Sciences and Epigenomics, as reported by MarketBeat.

Profitability

This table compares BARD1 Life Sciences and Epigenomics' net margins, return on equity and return on assets.

Earnings and Valuation

This table compares BARD1 Life Sciences and Epigenomics' top-line revenue, earnings per share and valuation.

Epigenomics has lower revenue, but higher earnings than BARD1 Life Sciences.

Summary

BARD1 Life Sciences beats Epigenomics on 1 of the 1 factors compared between the two stocks.